Karabo Study: Immune Correlates of Tuberculosis and non-Tuberculosis Infectious Morbidity in Southern African HIV- Exposed, Uninfected Infants
Principal Investigator Initiated

Principal Investigator - Dr. Kathleen Powis, MD, MPH

Study Objectives

Specific Aim 1: Define TB-related and TB-independent risk factors if morbidity and mortality in the first year of life among BCG vaccinated HE and HUU infants enrolled in the Karabo Study and a second ongoing study in Cape Town, South Africa, the InFANT Study (Innate Factors Associated with Nursing Transmission; funded by Canadian Institutes of Health Reseach), using multivariable logistic regression analysis.

Linking HIV Prevention and Postpartum Care: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a High-Risk Breastfeeding Population in Botswana (Tshireletso Study)
Principal Investigator Initiated

Primary Objectives

Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition
Principal Investigator Initiated

Principal Investigator: Joseph Moeketsi Makhema (MB.ChB, F.R.C.P)

Study Objectives:

Primary Objective:

Mitigating the impact of COVID-19 effects in adolescent reproductive health through self-testing: a mixed methods pilot study: “ICHEKE”
Principal Investigator Initiated

Principal Investigator - Lucy Mupfumi, PhD

Study Objectives

Mopati: A Pilot HIV Treatment Partner Intervention in Botswana
Principal Investigator Initiated

Principal Investigators - Professor Mosepele Mosepele, MD, MSc | Laura Bogart, PhD

Motsepe Wastewater Project
Principal Investigator Initiated

Principal Investigators: Prof. Sikhulile Moyo and Dr Shahin Lockman

Study Objectives: To evaluate the feasibility of testing wastewater from both urban and village settings in Botswana for;

Multi-Country Aetiology of Genital Ulcer Study (MAGUS)
Principal Investigator Initiated

Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH

Study Objectives:

Neurodevelopment In HEU Children Exposed In Utero To Dolutegravir or Efavirenz and HIV-Unexposed Children (Motheo Study)
Principal Investigator Initiated

Principal Investigator - Dr. Shahin Lockman MD, MPH | Dr. Adam Cassidy

Open-label access to dolutegravir for HIV-1 infected children and adolescents completing IMPAACT Studies P1093 and P2019: GSK205858
Principal Investigator Initiated

Principal Investigator - Dr. Shahin Lockman MD, MPH

Primary Objectives: To provide access to age appropriate formulations of dolutegravir (DTG), either as Tivicay or as fixed dose combination (FDC) abacavir/dolutegravir/lamivudine (ABC/DTG/3TC), in an open-label protocol to eligible subjects who have completed the P1093 or IMPAACT 2019 parent studies.

Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age
Principal Investigator Initiated

Principal Investigator: Gaerolwe R. Masheto, MD

Study Objectives:

Point-of-Care HIV Testing and Early Dolutegravir Use for Infants
Principal Investigator Initiated

Principal Investigator: Gbolahan Ajibola, MB, BS, MPH

Study Objectives

Primary Objectives

Point-of-Care HIV Testing and Early Dolutegravir Use for Infants (Moso Study)
Principal Investigator Initiated

Principal Investigator: Gbolahan Ajibola, MB, BS, MPH

Study Objectives:

Primary Aim 1: POC HIV testing of infants at birth

Post abortion care in Botswana: Impact of HIV status on outcomes
Principal Investigator Initiated

Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH

Study Objectives:

Post-acute sequelae of SARS-CoV-2 infection (PASC) / ‘Long Covid’: observational cohort: “Motlhala” Study
Principal Investigator Initiated

Principal Investigator - Dr. Shahin Lockman MD, MPH | Dr. Gaerolwe Masheto MD, PGDip FamMed | Dr. Kaelo Seatla MD

Study Objectives: Describe the prevalence and clinical manifestations of PASC in persons with confirmed SARS-CoV-2 (and comparator groups without history of SARS-CoV-2):

Potlako+ : A multilevel intervention to improve timely cancer detection and treatment initiation in Botswana
Principal Investigator Initiated

Principal Investigators - Dr. Scott Dryden-Peterson, MD, MSc | Dr. Neo M. Tapela, MD, MPH

Prevalence and outcomes of the usage of lumbar puncture in patients who presented with central nervous system symptoms at Princess Marina Hospital during the period 01/01/2014 to 31/03/2021
Principal Investigator Initiated

Principal Investigators - Nabila Youssouf PhD, Mosepele Mosepele MD, MSc | Sara Schwanke Khilji MD, MPH, FACP

Study Objectives: 

To determine the prevalence of lumbar puncture usage and outcomes of those who receive a lumbar puncture as compared to those who do not in patients who present to the hospital with neurological symptoms.

PRomoting Equity for Pregnant Adolescents in REsearch (PREPARE) in Botswana
Principal Investigator Initiated

Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH

Study Objectives:

 

Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV; v1.0 May 27, 2022; IND #158394; Site 12701/Gaborone
Principal Investigator Initiated

Principal Investigator: Ayotunde E. Omoz-Oarhe (MD, MPH)

Study Objectives:

Single, High-dose AmBisome to Reduce Excess mortality from Cryptococcal Meningitis (SHARE-CM)
Principal Investigator Initiated

Study Objectives: This is a 5-year (2021-2026) non-research grant funded by CDC to facilitate implementation of the short course regimen for the treatment of HIV-associated cryptococcal meningitis.

SOLIDARITY Trial: An international (multisite)randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care
Principal Investigator Initiated

Principal Investigator - Professor Mosepele Mosepele MD, MSc

Study Objectives: The primary outcome is in-hospital mortality from any cause, and the primary analyses are of mortality in all randomised patients. The major secondary outcomes are initiation of ventilation, and duration of hospital stay.